Liam Ratcliffe - Net Worth and Insider Trading

Liam Ratcliffe Net Worth

The estimated net worth of Liam Ratcliffe is at least $62 Million dollars as of 2024-05-11. Liam Ratcliffe is the Director, 10% Owner of Deciphera Pharmaceuticals Inc and owns about 2,146,308 shares of Deciphera Pharmaceuticals Inc (DCPH) stock worth over $54 Million. Liam Ratcliffe is the Director of Arvinas Inc and owns about 185,686 shares of Arvinas Inc (ARVN) stock worth over $6 Million. Liam Ratcliffe is also the Director of Cogent Biosciences Inc and owns about 224,443 shares of Cogent Biosciences Inc (COGT) stock worth over $2 Million. Besides these, Liam Ratcliffe also holds Aptinyx Inc (APTX) , Passage Bio Inc (PASG) , Array BioPharma Inc (ARRY) . Details can be seen in Liam Ratcliffe's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Liam Ratcliffe has not made any transactions after 2021-12-16 and currently still holds the listed stock(s).

Transaction Summary of Liam Ratcliffe

Liam Ratcliffe Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Liam Ratcliffe owns 16 companies in total, including Arvinas Inc (ARVN) , Passage Bio Inc (PASG) , and Cogent Biosciences Inc (COGT) among others .

Click here to see the complete history of Liam Ratcliffe’s form 4 insider trades.

Insider Ownership Summary of Liam Ratcliffe

Ticker	Comapny	Transaction Date	Type of Owner
ARVN	Arvinas Inc	2021-12-16	director & 10 percent owner
PASG	Passage Bio Inc	2020-03-03	director
COGT	Cogent Biosciences Inc	2018-04-03	director
		2018-06-25	director & 10 percent owner
		2016-06-21	director
		2018-05-24	10 percent owner
		2017-10-02	director & 10 percent owner
		2016-10-19	10 percent owner
		2013-11-21	10 percent owner
		2014-03-20	10 percent owner
		2013-04-10	10 percent owner
		2014-02-12	10 percent owner
		2013-11-27	other: Former 10% Beneficial Owner
		2013-11-20	other: Former 10% beneficial owner
		2021-08-09	director
		2022-12-29	director

Liam Ratcliffe Latest Holdings Summary

Liam Ratcliffe currently owns a total of 6 stocks. Among these stocks, Liam Ratcliffe owns 2,146,308 shares of Deciphera Pharmaceuticals Inc (DCPH) as of October 2, 2017, with a value of $54 Million and a weighting of 87.78%. Liam Ratcliffe owns 185,686 shares of Arvinas Inc (ARVN) as of December 16, 2021, with a value of $6 Million and a weighting of 9.42%. Liam Ratcliffe also owns 224,443 shares of Cogent Biosciences Inc (COGT) as of April 3, 2018, with a value of $2 Million and a weighting of 2.74%. The other 3 stocks Aptinyx Inc (APTX) , Passage Bio Inc (PASG) , Array BioPharma Inc (ARRY) have a combined weighting of 0.06% among all his current holdings.

Latest Holdings of Liam Ratcliffe

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DCPH	Deciphera Pharmaceuticals Inc	2017-10-02	2,146,308	25.36	54,430,371
ARVN	Arvinas Inc	2021-12-16	185,686	31.44	5,837,968
COGT	Cogent Biosciences Inc	2018-04-03	224,443	7.56	1,696,789
APTX	Aptinyx Inc	2018-06-25	368,345	0.10	35,361
PASG	Passage Bio Inc	2020-03-03	2,800	1.47	4,116
ARRY	Array BioPharma Inc	2013-09-27	0	38.95	0

Holding Weightings of Liam Ratcliffe

Liam Ratcliffe Form 4 Trading Tracker

According to the SEC Form 4 filings, Liam Ratcliffe has made a total of 0 transactions in Deciphera Pharmaceuticals Inc (DCPH) over the past 5 years. The most-recent trade in Deciphera Pharmaceuticals Inc is the acquisition of 375,000 shares on October 2, 2017, which cost Liam Ratcliffe around $6 Million.

According to the SEC Form 4 filings, Liam Ratcliffe has made a total of 5 transactions in Arvinas Inc (ARVN) over the past 5 years, including 2 buys and 3 sells. The most-recent trade in Arvinas Inc is the sale of 355,705 shares on December 16, 2021, which brought Liam Ratcliffe around $24 Million.

According to the SEC Form 4 filings, Liam Ratcliffe has made a total of 0 transactions in Cogent Biosciences Inc (COGT) over the past 5 years. The most-recent trade in Cogent Biosciences Inc is the acquisition of 137,500 shares on April 3, 2018, which cost Liam Ratcliffe around $7 Million.

More details on Liam Ratcliffe's insider transactions can be found in the Insider Trading History of Liam Ratcliffe table.

Insider Trading History of Liam Ratcliffe

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Liam Ratcliffe Trading Performance

GuruFocus tracks the stock performance after each of Liam Ratcliffe's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Liam Ratcliffe is 28.61%. GuruFocus also compares Liam Ratcliffe's trading performance to market benchmark return within the same time period. The performance of stocks bought by Liam Ratcliffe within 3 months outperforms 6 times out of 8 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Liam Ratcliffe's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Liam Ratcliffe

Average Return

Average return per transaction

Outperforming Transactions

3 out of 8 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	6.01
Relative Return to S&P 500(%)	9.66

Liam Ratcliffe Ownership Network

Ownership Network List of Liam Ratcliffe

No Data

Ownership Network Relation of Liam Ratcliffe

Liam Ratcliffe Owned Company Details

What does Arvinas Inc do?

Who are the key executives at Arvinas Inc?

Liam Ratcliffe is the director & 10 percent owner of Arvinas Inc. Other key executives at Arvinas Inc include Chief Medical Officer Ronald Peck , Chief Financial Officer Sean A Cassidy , and director & President and CEO John G Houston .

Arvinas Inc (ARVN) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Arvinas Inc (ARVN). Other recent insider transactions involving Arvinas Inc (ARVN) include a net sale of 11,074 shares made by John G Houston , a net sale of 3,447 shares made by Sean A Cassidy , and a net sale of 3,023 shares made by Ronald Peck .

In summary, during the past 3 months, insiders sold 10,298 shares of Arvinas Inc (ARVN) in total and bought 0 shares, with a net sale of 10,298 shares. During the past 18 months, 20,296 shares of Arvinas Inc (ARVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 20,296 shares.

Arvinas Inc (ARVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arvinas Inc Insider Transactions

No Available Data

What does Passage Bio Inc do?

Who are the key executives at Passage Bio Inc?

Liam Ratcliffe is the director of Passage Bio Inc. Other key executives at Passage Bio Inc include SVP & Interim CFO Kathleen Borthwick , Chief Medical Officer Mark S Forman , and Chief Financial Officer Simona King .

Passage Bio Inc (PASG) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Passage Bio Inc (PASG). Other recent insider transactions involving Passage Bio Inc (PASG) include a net sale of 13,506 shares made by Simona King , a net sale of 7,772 shares made by Alexandros Fotopoulos , and a net purchase of 1,192,577 shares made by Orbimed Advisors Llc .

In summary, during the past 3 months, insiders sold 3,108 shares of Passage Bio Inc (PASG) in total and bought 0 shares, with a net sale of 3,108 shares. During the past 18 months, 29,386 shares of Passage Bio Inc (PASG) were sold and 1,192,577 shares were bought by its insiders, resulting in a net purchase of 1,163,191 shares.

Passage Bio Inc (PASG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Passage Bio Inc Insider Transactions

No Available Data

What does Cogent Biosciences Inc do?

Who are the key executives at Cogent Biosciences Inc?

Liam Ratcliffe is the director of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include 10 percent owner & other: See Remarks Fairmount Funds Management Llc , Chief Legal Officer Evan Kearns , and Chief Financial Officer John L. Green .

Cogent Biosciences Inc (COGT) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Cogent Biosciences Inc (COGT). Other recent insider transactions involving Cogent Biosciences Inc (COGT) include a net purchase of 800,000 shares made by Fairmount Funds Management Llc ,

In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cogent Biosciences Inc Insider Transactions

No Available Data

What does Aptinyx Inc do?

Who are the key executives at Aptinyx Inc?

Liam Ratcliffe is the director & 10 percent owner of Aptinyx Inc. Other key executives at Aptinyx Inc include director & CEO and President Norbert G Riedel , CFO and CBO Ashish Khanna , and 10 percent owner Bain Capital Life Sciences Investors, Llc .

Aptinyx Inc (APTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aptinyx Inc (APTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptinyx Inc (APTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aptinyx Inc (APTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aptinyx Inc Insider Transactions

No Available Data

What does PDS Biotechnology Corp do?

Who are the key executives at PDS Biotechnology Corp?

Liam Ratcliffe is the director of PDS Biotechnology Corp. Other key executives at PDS Biotechnology Corp include Senior VP & General Counsel Spencer D. Brown , Chief Financial Officer Matthew C Hill , and director & 10 percent owner Delyle W Bloomquist .

PDS Biotechnology Corp (PDSB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PDS Biotechnology Corp (PDSB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PDS Biotechnology Corp (PDSB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PDS Biotechnology Corp (PDSB)'s detailed insider trading history can be found in Insider Trading Tracker table.

PDS Biotechnology Corp Insider Transactions

No Available Data

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Liam Ratcliffe is the 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , a net purchase of 10,000 shares made by Fishman Corey N. , and a net sale of 3,365 shares made by Sailaja Puttagunta .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iterum Therapeutics PLC Insider Transactions

No Available Data

What does Deciphera Pharmaceuticals Inc do?

Who are the key executives at Deciphera Pharmaceuticals Inc?

Liam Ratcliffe is the director & 10 percent owner of Deciphera Pharmaceuticals Inc. Other key executives at Deciphera Pharmaceuticals Inc include EVP & Chief Medical Officer Matthew L Sherman , Chief Financial Officer Thomas Patrick Kelly , and Chief Commercial Officer Daniel C. Martin .

Deciphera Pharmaceuticals Inc (DCPH) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Deciphera Pharmaceuticals Inc (DCPH). Other recent insider transactions involving Deciphera Pharmaceuticals Inc (DCPH) include a net sale of 26,559 shares made by Daniel C. Martin , a net sale of 14,587 shares made by Matthew L Sherman , and a net sale of 11,601 shares made by Thomas Patrick Kelly .

In summary, during the past 3 months, insiders sold 0 shares of Deciphera Pharmaceuticals Inc (DCPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 154,121 shares of Deciphera Pharmaceuticals Inc (DCPH) were sold and 1,687,666 shares were bought by its insiders, resulting in a net purchase of 1,533,545 shares.

Deciphera Pharmaceuticals Inc (DCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Deciphera Pharmaceuticals Inc Insider Transactions

No Available Data

What does iRhythm Technologies Inc do?

Who are the key executives at iRhythm Technologies Inc?

Liam Ratcliffe is the 10 percent owner of iRhythm Technologies Inc. Other key executives at iRhythm Technologies Inc include CLO & EVP RA/QA MrktAcs & Gov Patrick Michael Murphy , Chief Financial Officer Brice Bobzien , and EVP & CMO & CSO Minang Turakhia .

iRhythm Technologies Inc (IRTC) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in iRhythm Technologies Inc (IRTC). Other recent insider transactions involving iRhythm Technologies Inc (IRTC) include a net sale of 20,569 shares made by Daniel G. Wilson , a net sale of 13,101 shares made by Patrick Michael Murphy , and a net sale of 5,504 shares made by Mark J. Day .

In summary, during the past 3 months, insiders sold 42,096 shares of iRhythm Technologies Inc (IRTC) in total and bought 0 shares, with a net sale of 42,096 shares. During the past 18 months, 76,173 shares of iRhythm Technologies Inc (IRTC) were sold and 9,755 shares were bought by its insiders, resulting in a net sale of 66,418 shares.

iRhythm Technologies Inc (IRTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

iRhythm Technologies Inc Insider Transactions

No Available Data

What does MEI Pharma Inc do?

Who are the key executives at MEI Pharma Inc?

Liam Ratcliffe is the 10 percent owner of MEI Pharma Inc. Other key executives at MEI Pharma Inc include Chief Medical Officer Richard G Ghalie , 10 percent owner Amin Nathoo , and 10 percent owner Funicular Funds, Lp .

MEI Pharma Inc (MEIP) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in MEI Pharma Inc (MEIP). Other recent insider transactions involving MEI Pharma Inc (MEIP) include a net purchase of 201,660 shares made by Anson Funds Management Lp , a net purchase of 134,440 shares made by Funicular Funds, Lp , and a net purchase of 81,500 shares made by Baltic Charles V. Iii .

In summary, during the past 3 months, insiders sold 0 shares of MEI Pharma Inc (MEIP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MEI Pharma Inc (MEIP) were sold and 340,175 shares were bought by its insiders, resulting in a net purchase of 340,175 shares.

MEI Pharma Inc (MEIP)'s detailed insider trading history can be found in Insider Trading Tracker table.

MEI Pharma Inc Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

Liam Ratcliffe is the 10 percent owner of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

What does Chimerix Inc do?

Who are the key executives at Chimerix Inc?

Liam Ratcliffe is the 10 percent owner of Chimerix Inc. Other key executives at Chimerix Inc include Principal Accounting Officer David Jakeman , Chief Business Officer Michael T. Andriole , and director & Chief Executive Officer Michael A. Sherman .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Chimerix Inc (CMRX). Other recent insider transactions involving Chimerix Inc (CMRX) include a net purchase of 60,000 shares made by Fred A Middleton , a net sale of 9,500 shares made by David Jakeman , and a net purchase of 87,000 shares made by Michael A. Sherman .

In summary, during the past 3 months, insiders sold 6,344 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 6,344 shares. During the past 18 months, 13,184 shares of Chimerix Inc (CMRX) were sold and 173,750 shares were bought by its insiders, resulting in a net purchase of 160,566 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chimerix Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Liam Ratcliffe is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Concert Pharmaceuticals Inc (CNCE). Other recent insider transactions involving Concert Pharmaceuticals Inc (CNCE) include a net sale of 16,093 shares made by Nancy Stuart , a net sale of 12,999 shares made by James V Cassella , and a net sale of 11,386 shares made by Jeffrey A Munsie .

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 61,104 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 61,104 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does Oxford Immunotec Global PLC do?

Who are the key executives at Oxford Immunotec Global PLC?

Liam Ratcliffe is the other: Former 10% Beneficial Owner of Oxford Immunotec Global PLC. Other key executives at Oxford Immunotec Global PLC include director & Chief Executive Officer Peter Wrighton-smith , Chief Financial Officer Mclaughlin Matthew T E , and Chief Operating Officer Stefan C Linn .

Oxford Immunotec Global PLC (OXFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oxford Immunotec Global PLC (OXFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oxford Immunotec Global PLC (OXFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oxford Immunotec Global PLC (OXFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oxford Immunotec Global PLC Insider Transactions

No Available Data

What does Relypsa Inc do?

Who are the key executives at Relypsa Inc?

Liam Ratcliffe is the other: Former 10% beneficial owner of Relypsa Inc. Other key executives at Relypsa Inc include SVP & Chief Commercial Officer J. Scott Garland , SVP & Chief Technology Officer Wilhelm Stahl , and See Remarks Ronald A. Krasnow .

Relypsa Inc (RLYP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Relypsa Inc (RLYP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Relypsa Inc (RLYP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Relypsa Inc (RLYP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Relypsa Inc Insider Transactions

No Available Data

What does Eliem Therapeutics Inc do?

Who are the key executives at Eliem Therapeutics Inc?

Liam Ratcliffe is the director of Eliem Therapeutics Inc. Other key executives at Eliem Therapeutics Inc include Chief Accounting Officer Emily Pimblett , director & 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Ai Eti Llc .

Eliem Therapeutics Inc (ELYM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eliem Therapeutics Inc (ELYM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eliem Therapeutics Inc (ELYM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eliem Therapeutics Inc (ELYM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eliem Therapeutics Inc Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

Liam Ratcliffe is the director of Disc Medicine Inc. Other key executives at Disc Medicine Inc include 10 percent owner Atlas Venture Fund X, L.p. , director & 10 percent owner Orbimed Advisors Llc , and director & 10 percent owner Mona Ashiya .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, Liam Ratcliffe made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 1,106,612 shares made by Atlas Venture Fund X, L.p. , a net sale of 297,652 shares made by Kevin Bitterman , and a net sale of 20,634 shares made by Joanne Bryce .

In summary, during the past 3 months, insiders sold 28,918 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 28,918 shares. During the past 18 months, 3,899,867 shares of Disc Medicine Inc (IRON) were sold and 652,175 shares were bought by its insiders, resulting in a net sale of 3,247,692 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

Liam Ratcliffe Mailing Address

Above is the net worth, insider trading, and ownership report for Liam Ratcliffe. You might contact Liam Ratcliffe via mailing address: C/o Access Industries, Inc, 40 West 57th St, 28th Floor, New York Ny 10019.

Discussions on Liam Ratcliffe

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.